OraSure Technologies (NASDAQ:OSUR) Downgraded by StockNews.com to “Hold”

StockNews.com downgraded shares of OraSure Technologies (NASDAQ:OSUR) from a buy rating to a hold rating in a report issued on Tuesday.

OraSure Technologies Price Performance

Shares of OSUR stock opened at $3.31 on Tuesday. The company has a market cap of $246.91 million, a PE ratio of 22.07 and a beta of -0.02. The stock’s 50 day simple moving average is $3.75 and its two-hundred day simple moving average is $3.98. OraSure Technologies has a 1 year low of $2.68 and a 1 year high of $7.43.

Insiders Place Their Bets

In other OraSure Technologies news, Director John P. Kenny bought 47,659 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was acquired at an average cost of $3.17 per share, for a total transaction of $151,079.03. Following the completion of the transaction, the director now owns 70,915 shares in the company, valued at $224,800.55. This trade represents a 204.93 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Kenneth J. Mcgrath acquired 64,000 shares of the stock in a transaction on Thursday, February 27th. The stock was bought at an average cost of $3.15 per share, with a total value of $201,600.00. Following the completion of the transaction, the chief financial officer now owns 371,013 shares in the company, valued at $1,168,690.95. This trade represents a 20.85 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 190,284 shares of company stock valued at $600,348 over the last three months. 3.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On OraSure Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its stake in OraSure Technologies by 23.1% in the fourth quarter. Renaissance Technologies LLC now owns 2,774,443 shares of the medical instruments supplier’s stock worth $10,016,000 after acquiring an additional 521,400 shares during the period. American Century Companies Inc. boosted its stake in shares of OraSure Technologies by 11.4% during the fourth quarter. American Century Companies Inc. now owns 2,345,837 shares of the medical instruments supplier’s stock valued at $8,468,000 after purchasing an additional 240,224 shares in the last quarter. Millennium Management LLC raised its stake in OraSure Technologies by 16.7% in the fourth quarter. Millennium Management LLC now owns 2,158,450 shares of the medical instruments supplier’s stock worth $7,792,000 after buying an additional 308,420 shares in the last quarter. Geode Capital Management LLC lifted its holdings in OraSure Technologies by 2.6% during the fourth quarter. Geode Capital Management LLC now owns 1,844,139 shares of the medical instruments supplier’s stock worth $6,659,000 after buying an additional 46,325 shares during the period. Finally, Systematic Financial Management LP boosted its position in OraSure Technologies by 33.7% during the 4th quarter. Systematic Financial Management LP now owns 1,673,609 shares of the medical instruments supplier’s stock valued at $6,042,000 after acquiring an additional 421,497 shares in the last quarter. Institutional investors own 93.50% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.